A detailed history of Grimes & Company, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Grimes & Company, Inc. holds 93,146 shares of AMGN stock, worth $29 Million. This represents 0.82% of its overall portfolio holdings.

Number of Shares
93,146
Previous 91,431 1.88%
Holding current value
$29 Million
Previous $26.3 Million 0.57%
% of portfolio
0.82%
Previous 0.88%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 17, 2024

BUY
$268.87 - $324.56 $461,112 - $556,620
1,715 Added 1.88%
93,146 $26.5 Million
Q4 2023

Jan 24, 2024

BUY
$255.7 - $288.46 $165,437 - $186,633
647 Added 0.71%
91,431 $26.3 Million
Q3 2023

Oct 19, 2023

SELL
$218.65 - $271.46 $852,735 - $1.06 Million
-3,900 Reduced 4.12%
90,784 $24.4 Million
Q2 2023

Jul 19, 2023

BUY
$214.27 - $253.37 $55,067 - $65,116
257 Added 0.27%
94,684 $21 Million
Q1 2023

Apr 20, 2023

BUY
$225.79 - $275.2 $668,564 - $814,867
2,961 Added 3.24%
94,427 $22.8 Million
Q4 2022

Jan 25, 2023

BUY
$229.03 - $291.01 $323,848 - $411,488
1,414 Added 1.57%
91,466 $0
Q3 2022

Oct 28, 2022

BUY
$224.46 - $253.15 $131,758 - $148,599
587 Added 0.66%
90,052 $20.3 Million
Q2 2022

Jul 22, 2022

SELL
$230.71 - $256.74 $1.98 Million - $2.2 Million
-8,579 Reduced 8.75%
89,465 $21.8 Million
Q1 2022

May 06, 2022

BUY
$219.27 - $242.57 $1.42 Million - $1.57 Million
6,463 Added 7.06%
98,044 $23.7 Million
Q4 2021

Feb 01, 2022

BUY
$198.88 - $227.6 $367,530 - $420,604
1,848 Added 2.06%
91,581 $20.6 Million
Q3 2021

Nov 08, 2021

BUY
$212.27 - $248.7 $1.03 Million - $1.21 Million
4,869 Added 5.74%
89,733 $19.1 Million
Q2 2021

Aug 04, 2021

BUY
$233.58 - $259.14 $785,295 - $871,228
3,362 Added 4.13%
84,864 $20.7 Million
Q1 2021

May 12, 2021

BUY
$221.91 - $258.6 $3.52 Million - $4.1 Million
15,849 Added 24.14%
81,502 $20.3 Million
Q4 2020

Feb 02, 2021

BUY
$216.38 - $257.67 $2.25 Million - $2.68 Million
10,398 Added 18.82%
65,653 $15.1 Million
Q3 2020

Nov 12, 2020

SELL
$234.65 - $260.95 $491,591 - $546,690
-2,095 Reduced 3.65%
55,255 $14 Million
Q2 2020

Jul 31, 2020

SELL
$197.81 - $242.74 $106,026 - $130,108
-536 Reduced 0.93%
57,350 $13.5 Million
Q1 2020

May 05, 2020

SELL
$182.24 - $241.7 $768,323 - $1.02 Million
-4,216 Reduced 6.79%
57,886 $11.7 Million
Q4 2019

Feb 05, 2020

SELL
$189.21 - $243.2 $382,582 - $491,750
-2,022 Reduced 3.15%
62,102 $15 Million
Q3 2019

Nov 05, 2019

BUY
$174.11 - $208.62 $130,930 - $156,882
752 Added 1.19%
64,124 $12.4 Million
Q2 2019

Jul 30, 2019

BUY
$166.7 - $195.41 $148,196 - $173,719
889 Added 1.42%
63,372 $11.7 Million
Q1 2019

May 02, 2019

BUY
$180.87 - $203.88 $281,795 - $317,645
1,558 Added 2.56%
62,483 $11.9 Million
Q4 2018

Feb 01, 2019

BUY
$178.4 - $208.25 $60,656 - $70,805
340 Added 0.56%
60,925 $11.9 Million
Q3 2018

Nov 09, 2018

BUY
$185.29 - $208.89 $163,425 - $184,240
882 Added 1.48%
60,585 $12.6 Million
Q2 2018

Aug 10, 2018

SELL
$166.05 - $186.51 $199,758 - $224,371
-1,203 Reduced 1.98%
59,703 $11 Million
Q1 2018

May 07, 2018

BUY
$169.43 - $198.0 $1.1 Million - $1.28 Million
6,483 Added 11.91%
60,906 $10.4 Million
Q4 2017

Feb 05, 2018

BUY
$168.79 - $188.59 $106,844 - $119,377
633 Added 1.18%
54,423 $9.46 Million
Q3 2017

Nov 03, 2017

BUY
$167.29 - $191.0 $9 Million - $10.3 Million
53,790
53,790 $10 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $167B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Grimes & Company, Inc. Portfolio

Follow Grimes & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Grimes & Company, Inc. with notifications on news.